Form D · Biotechnology
ImmuneBridge Inc.
San Francisco, CA · CIK 0001960306
Offering snapshot reported Apr 2, 2025 · SEC filing
- Reported sold
- $5.63M Offering amount: $7.13M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 2, 2025 | Initial | $5,632,000 | No comparison | 6 | SEC filing |
| Jan 10, 2023 | Initial | $10,150,000 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-542721
Includes the issuance of shares of preferred stock upon conversion of simple agreements for future equity.
Source: Form D, filed Apr 2, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Omri Amirav Drory | Director |
| Gregory A. Bonfiglio | Director |
| Thomas Farrell | Director |
| Nadiya Ishnazarova | Director |
| Alicia Jackson | Director |
| Stuart Alexander Jacobson | Director, Executive |
| Dylan Morris | Director |
| Peretz Partensky | Director, Executive |
| Mary Kim Warren | Director |
| Cheryl Zimberlin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2122 Bryant St
San Francisco, CA, 94110
San Francisco, CA, 94110